The updated elPrep 5 sequencing processing platform is said to run 8 to 16 times faster than GATK while producing similar results, thanks to parallel computing and new algorithms.
The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
The deal gives Definitive Healthcare a foothold in the genomics market as it looks to build its own genomic data pipeline to serve through PatientFinder's CohortBuilder tool.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
